MX368656B - Métodos mejorados para la producción de polipéptidos recombinantes. - Google Patents

Métodos mejorados para la producción de polipéptidos recombinantes.

Info

Publication number
MX368656B
MX368656B MX2016007207A MX2016007207A MX368656B MX 368656 B MX368656 B MX 368656B MX 2016007207 A MX2016007207 A MX 2016007207A MX 2016007207 A MX2016007207 A MX 2016007207A MX 368656 B MX368656 B MX 368656B
Authority
MX
Mexico
Prior art keywords
polypeptide
fusion
pro
production methods
recombinant polypeptide
Prior art date
Application number
MX2016007207A
Other languages
English (en)
Other versions
MX2016007207A (es
Inventor
Kopetzki Erhard
Niewoehner Jens
Maier Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016007207A publication Critical patent/MX2016007207A/es
Publication of MX368656B publication Critical patent/MX368656B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para producir un polipéptido de fusión que comprende los pasos que consiste en a) cultivar una célula de mamífero que comprende un ácido nucleico que codifica un polipéptido de fusión variante en donde la secuencia de aminoácidos del polipéptido de fusión ha sido modificada por medio del reemplazo en un pro-polipéptido de fusión del sitio de escisión de proteasa endógeno entre el pro-péptido y el polipéptido de fusión con un sitio de escisión de proteasa exógeno (con respecto a los orígenes de las partes del polipéptido de fusión) o artificial y b) recuperar el polipéptido de fusión o pro-polipéptido de fusión de la célula o el medio de cultivo y producir de ese modo el polipéptido de fusión (recombinante).
MX2016007207A 2013-12-20 2014-12-10 Métodos mejorados para la producción de polipéptidos recombinantes. MX368656B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198738 2013-12-20
PCT/EP2014/077196 WO2015091144A1 (en) 2013-12-20 2014-12-10 Improved recombinant polypeptide production methods

Publications (2)

Publication Number Publication Date
MX2016007207A MX2016007207A (es) 2016-07-21
MX368656B true MX368656B (es) 2019-10-10

Family

ID=49886715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007207A MX368656B (es) 2013-12-20 2014-12-10 Métodos mejorados para la producción de polipéptidos recombinantes.

Country Status (11)

Country Link
US (2) US10370692B2 (es)
EP (1) EP3083977B1 (es)
JP (1) JP6618912B2 (es)
KR (1) KR20160098277A (es)
CN (1) CN105829542A (es)
BR (1) BR112016012229A2 (es)
CA (1) CA2929149A1 (es)
HK (1) HK1223980A1 (es)
MX (1) MX368656B (es)
RU (2) RU2019134445A (es)
WO (1) WO2015091144A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120665195A (zh) 2015-06-24 2025-09-19 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
JP7512210B2 (ja) 2018-09-21 2024-07-08 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 新規インターロイキン２およびその使用
AU2019344875B2 (en) * 2018-09-21 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin 2 and use thereof
KR102027955B1 (ko) 2019-01-24 2019-10-02 이현종 로스터 후드용 내부커버 및 이의 제조방법
AU2021226352A1 (en) * 2020-02-25 2022-09-29 Momenta Pharmaceuticals, Inc. Enzymes for sialylation of glycans
IT202000032423A1 (it) * 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita
CA3237801A1 (en) 2021-11-11 2023-05-19 John Diener Relaxin-2 fusion protein analogs and methods of using same
WO2024238955A2 (en) 2023-05-18 2024-11-21 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
CA2123307A1 (en) 1991-11-26 1993-06-10 Phillip M. Friden Process for the preparation of transferrin receptor specific antibody-neuro-pharmaceutical or diagnostic agent conjugates
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
HK1042098B (zh) 1998-10-16 2009-10-30 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
IL129427A0 (en) 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
SE9901428D0 (sv) 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
CA2412882A1 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0412186D0 (en) * 2004-05-28 2004-06-30 Univ Cambridge Tech Production of recombinant protein
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
EP2520586A1 (en) 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
ES2393373T3 (es) * 2006-08-31 2012-12-20 F. Hoffmann-La Roche Ag Método para la producción de factor-I de crecimiento similar a la insulina
US8759066B2 (en) * 2008-04-07 2014-06-24 Zymogenetics, Inc. Thrombin activator compositions and methods of making and using the same
AU2009274127A1 (en) 2008-07-21 2010-01-28 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
CA2757669A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
WO2012075037A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
WO2012087835A2 (en) 2010-12-22 2012-06-28 Boston Biomedical Research Institute Compositions and methods for enhancing protein folding
TR201815420T4 (tr) 2011-03-29 2018-11-21 Roche Glycart Ag Antikor fc varyantları.
AU2012244816B2 (en) 2011-04-20 2015-12-10 Roche Glycart Ag Method and constructs for the pH dependent passage of the blood-brain-barrier
KR20140135959A (ko) * 2012-02-29 2014-11-27 에프. 호프만-라 로슈 아게 온-컬럼 효소적 절단
EP2668901A1 (en) 2012-05-31 2013-12-04 Roche Diagniostics GmbH Sensor insertion assembly, sensor cartridge, and inserter
KR102036262B1 (ko) 2012-08-29 2019-10-24 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀

Also Published As

Publication number Publication date
JP6618912B2 (ja) 2019-12-11
HK1223980A1 (zh) 2017-08-11
CN105829542A (zh) 2016-08-03
BR112016012229A2 (pt) 2017-09-26
US20190271021A1 (en) 2019-09-05
RU2711322C1 (ru) 2020-01-16
RU2019134445A (ru) 2019-12-20
EP3083977A1 (en) 2016-10-26
KR20160098277A (ko) 2016-08-18
US11098338B2 (en) 2021-08-24
US20160326562A1 (en) 2016-11-10
WO2015091144A1 (en) 2015-06-25
JP2017500040A (ja) 2017-01-05
US10370692B2 (en) 2019-08-06
MX2016007207A (es) 2016-07-21
CA2929149A1 (en) 2015-06-25
RU2016128367A (ru) 2018-01-25
EP3083977B1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
MX368656B (es) Métodos mejorados para la producción de polipéptidos recombinantes.
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
MX2018002121A (es) Elaboracion de fosfatasas alcalinas.
BR112018004377A2 (pt) cepas de levedura para a expressão e secreção de proteínas heterólogas em temperaturas elevadas
MY200939A (en) Methods Of Producing Long Acting Ctp-Modified Growth Hormone Polypeptides
MX384960B (es) Cultivo celular metabolicamente optimizado
MX2015011968A (es) Cambio de temperatura para una expresión con mayor rendimiento de polipéptidos en levaduras y otras células transformadas.
MX2016014222A (es) Celulas novedosas de vertebrados y metodos para la expresion recombinante de un polipeptido de interes.
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
MX2015010078A (es) Uso de polipeptidos con actividad proteasa en alimentos para animales.
IN2014CN03077A (es)
PE20211303A1 (es) Polipeptidos del factor vii de accion corta
MY182443A (en) Method of producing lipid
WO2013068602A3 (en) Method for the production of polypeptides
EA028913B9 (ru) Получение антител высокой чистоты в pichia pastoris
WO2014044626A3 (en) Process for producing gelatin employing aspergillopepsin ii
MX2013005749A (es) Composiciones y metodos para producir enterocinasa en levaduras.
MY184625A (en) Methods of producing long acting ctp-modified growth hormone polypeptides
MX2013000842A (es) Produccion a base de plantas de las proteínas heterólogas.
PH12015500459A1 (en) Picornavirus-like particle production in plants
IN2014MN00935A (es)
AR094716A1 (es) Utilización de una cepa procariótica de auxotrofía para aminoácidos revertida para la producción recombinante de un polipéptido
MX2013012163A (es) Plantas que tienen uno o mas rasgos mejorados relacionados con el rendimiento y metodos para elaborar los mismos.

Legal Events

Date Code Title Description
FG Grant or registration